BACKGROUND

Current treatments for neuropathic/inflammatory pains display side-effects and weak efficiency.

HOW IT WORKS

TAFA4 is an analgesic drug. It can be formulated in a form of solution for sub-cutaneous (SC) administration. It is indicated for neuropathic and inflammatory pain (possible association with very low amount of pregabalin).

TAFA4 is a human short protein (100 amino acids) with high affinity for PRF-1 on macrophages. The binding of TAFA4 to peripheral nervous system (dorsal root ganglia) reverses pain more than 4 hours after injection.

RESULTS

• TAFA4 has strong analgesic effects against carrageenan- and Spared Nerve Injury-induced mechanical hypersensitivity in mice
• Its Mechanism of Action likely involves its interaction with the PRF1 highly enriched in macrophages
• No need to cross blood brain barrier for function

KEY BENEFITS vs. STATE OF THE ART

• Original target
• High efficiency: similar to Pregabaline with a 100 fold lower dose
• TAFA4 can be easily produced in E. Coli
• No side effect observed
• Long lasting effect
• Non-opioid

DEVELOPMENT STATUS

• Target identification on-going on dorsal root ganglia
• TAFA4 safety study on immune system